Ivarmacitinib sulfate

硫酸艾玛昔替尼

Report date: 2026/04/13 20:02:18
NME

Base Information

Drug NameIvarmacitinib sulfate
Drug Alias NameARQ 252 active ingredient艾速达SHR-0302ARQ-252ARQ-255
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK1 inhibitorsSignal transducer and activator of transcription 3 inhibitors
TargetsTyrosine-protein kinase JAK1Signal transducer and activator of transcription 3
Therapy Area/IndicationsSedationNon-radiographic axial spondyloarthritisMetastatic breast cancer +[20] 
Global Approved IndicationsSpondylitis, Ankylosing
Approved Indications in ChinaSpondylitis, Ankylosing
Original Approved Country/TerritoryMainland China
Original Approved Date2025/03/18
Country/TerritoryCanadaUnited StatesUkraine +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesFujian Cancer HospitalArcutis Biotherapeutics IncHenan Provincial Cancer Hospital +[10] 
Inactive CompaniesN/A
Active IndicationsSedationNon-radiographic axial spondyloarthritisMetastatic breast cancer +[18] 
Inactive IndicationsEczemaHepatic Insufficiency

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG